Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV
Author(s)
Sarah Samorodnitsky
Chris H. Wendt
Jason V. Baker
Gary Collins
Monica Kruk
Eric F. Lock
Roger Paredes
Selvamuthu Poongulali
Danielle O. Weise
Alan Winston
Robin Wood
Ken M. Kunisaki
INSIGHT START Pulmonary Substudy Group
Bitten Aagaard
Paul Jansson
Mary Pearson
Abdel G. Babiker
Alejandro Arenas‐Pinto
Nafisah B Atako
Edward A. Dennis
S. Forcat
Fleur Hudson
B. Jackson
Daphne Maas
Caitlin G. Purvis
C. T. Russell
Sean Emery
Cara Donahue Carey
Megan Clewett
Simone Jacoby
Fred M. Gordin
Michael J. Vjecha
Alejandro Sanchez
Guido Ruggero Loria
Marcela Doldán
André de Moricz
K. Tillmann
V Müller
Giota Touloumi
Vicky Gioukari
Olga Anagnostou
Pablo Herrero
Patricia López
Anchalee Avihingsanon
Patsamon Rerksirikul
Site Investigators by Country and institution
Eliana Loiza
Verónica Mingrone
Sofia Lupo
F Marconi
D. Daniel
Ana Crinejo
Martyn A. French
L. Barba
Diane Rowling
E. Warzywoda
Mark Bloch
Swati Agrawal
Dominic E. Dwyer
Bruce Taylor
Lida van Petersen
Luc Mertens
S De Wit
K. Kabamba
Marcelo Wolff
G Allendes
Matti Ristola
O. Debham
Henrik Jessen
Arne Jessen
S. Wiebecke
Hartwig Klinker
Gerd Fätkenheuer
Clara Lehmann
I. Knaevelsrud
M. Rittweger
Albrecht Stöhr
Karl S. Oláh
Bernhard Schaaf
Martin Hower
Thomas Harrer
Ellen G. Harrer
A. Skoutelis
Vasilios Papastamopoulos
Simeon Metallidis
Οlga Tsachouridou
Sanjay Pujari
Abhishek Chitalikar
N. Kumarasamy
Faith Esther Beulah
Eduardo Shahar
Eynat Kedem
Dan Turner
Juan Sierra Madero
Carlos Madrigal
Kamal Marhoum El Filali
I. Erradey
Ernest Ekong
Nnakelu Eriobu
Javier Valencia
Manuel Garza-León
Esmelda Montalbán
Raúl Salazar
Jesús Vega
M. del Portal
Fernando Mendo
Elżbieta Bąkowska
Anna Ignatowska
Marcin Czarnecki
Aleksandra Szymczak
Robin Wood
M. Rattley
S. Pillay
Rosie Mngqibisa
Thoko Ndaba
Paradise Madlala
Vicente Estrada
M.E. Rodrigo
M. Gutierrez
José Muñóz
David Dalmau
Cristina Badía
Bonaventura Clotet
Josep M. Llibre
Kiat Ruxrungtham
Sivaporn Gatechompol
Sasisopin Kiertiburanakul
Nutaporn Sanmeema
Chureeratana Bowonwatanuwong
U. Ampunpong
Wisit Prasithsirikul
Supeda Thongyen
Ploenchan Chetchotisakd
Siriluck Anunnatsiri
Winai Ratanasuwan
Peerawong Werarak
Cissy Kityo
H. Mugerwa
Paula Munderi
Joseph Lutaakome
Amanda Clarke
Andrew Bexley
Sayantan Das
Amandip Sahota
C R Emerson
Shannon McKernan
Margaret Johnson
M Youle
Jonathan Ross
J. W. Harding
Stephen Kegg
Tarik Moussaoui
Fangfang Chen
Sharonann Lynch
Andrew De Burgh-Thomas
W. A. I. P. Karunaratne
David H. Dockrell
C. Bowman
Alan Winston
Borja Mora‐Peris
David Chadwick
Peter Lambert
Neeraj Desai
W. Carter
Keith Henry
R. Givot
M. Chow
B. Holloway
Stephen E. Weis
I. Vecino
Richard M. Novak
Gabriel J. Culbert
Aimee Wilkin
Libyadda J. Mosley
Nathan M. Thielman
J. Granholm
Victoria Watson
C. Clark
Joary Vargas Santana
I. Boneta
Indira Brar
Linda Makohon
Rodger D. MacArthur
Marti J. Farrough
M. Frank
Sarah J. Parker
Ellen Tedaldi
Mayra C. Santiago
Susan L. Koletar
Heather Harber
D. Thomas
Ioana Bica
Benjamin Adams
C. VAN DAM
Michael A. Kolber
Karen Moreno
Amanda Brown
B Wade
Date Issued
23 de marzo de 2023
Type
Article
Volume
13
Issue
1
Start Page
4749
End Page
4749
Abstract
Abstract Chronic obstructive pulmonary disease (COPD) is among the leading causes of death worldwide and HIV is an independent risk factor for the development of COPD. However, the etiology of this increased risk and means to identify persons with HIV (PWH) at highest risk for COPD have remained elusive. Biomarkers may reveal etiologic pathways and allow better COPD risk stratification. We performed a matched case:control study of PWH in the Strategic Timing of Antiretoviral Treatment (START) pulmonary substudy. Cases had rapid lung function decline (> 40 mL/year FEV 1 decline) and controls had stable lung function (+ 20 to − 20 mL/year). The analysis was performed in two distinct groups: (1) those who were virally suppressed for at least 6 months and (2) those with untreated HIV (from the START deferred treatment arm). We used linear mixed effects models to test the relationship between case:control status and blood concentrations of pneumoproteins (surfactant protein-D and club cell secretory protein), and biomarkers of inflammation (IL-6 and hsCRP) and coagulation (d-dimer and fibrinogen); concentrations were measured within ± 6 months of first included spirometry. We included an interaction with treatment group (untreated HIV vs viral suppression) to test if associations varied by treatment group. This analysis included 77 matched case:control pairs in the virally suppressed batch, and 42 matched case:control pairs in the untreated HIV batch (n = 238 total) who were followed for a median of 3 years. Median (IQR) CD4 + count was lowest in the controls with untreated HIV at 674 (580, 838). We found no significant associations between case:control status and pneumoprotein or biomarker concentrations in either virally suppressed or untreated PWH. In this cohort of relatively young, recently diagnosed PWH, concentrations of pneumoproteins and biomarkers of inflammation and coagulation were not associated with subsequent rapid lung function decline. Trial registration: NCT00867048 and NCT01797367.
Subjects